Benefits of ADHD Treatment in Detained People
ConditionADHD
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorStéphanie Baggio
About this trial
Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.
Eligibility criteria
Qualifiers
age between 18 and 65
good command of French
stay in prison approx. 4 months at eligibility visit
endorsing clinical diagnostic criteria for DSM-5 ADHD
Disqualifiers
presence of an acute uncontrolled comorbid psychiatric disorder
medical contraindication to stimulant prescription
potential adverse interaction with another medication
already receive ADHD treatment
Trial design
Treatments tested in this trial
- Concerta
- Placebo
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Stéphanie Baggio
Lead sponsor
University Hospital, Geneva
Sponsor institution
University of Lausanne
Collaborator
University of Geneva, Switzerland
Collaborator
Netherlands Institute for the Study of Crime
Collaborator
School of Health Sciences Fribourg
Collaborator
Source ClinicalTrials.gov